Shares of Sun Pharmaceutical Industries Limited surged more than 3% after the company reported robust consolidated financial results for the third quarter ended December 31, 2025. The results, approved by the Board of Directors at its meeting held today, reflected healthy growth in revenue, profitability, and operating margins, boosting investor confidence.
For Q3FY26, Sun Pharma reported revenue from operations of ₹15,520.5 crore, compared with ₹13,675.4 crore in Q3FY25, marking a year-on-year growth of 13.5%. The improvement was driven by steady performance across key markets and a strong contribution from its global businesses.
Operating performance strengthened further during the quarter. EBITDA rose 23.4% year-on-year to ₹4,948.5 crore from ₹4,009.0 crore in the same period last year. As a result, the EBITDA margin expanded to 31.9% in Q3FY26, up from around 29.9% in Q3FY25, highlighting better cost efficiency and operating leverage.
Profitability also showed solid improvement. Profit before exceptional items and tax increased to ₹4,716.6 crore, compared with ₹3,792.6 crore in Q3FY25, registering a year-on-year rise of 24.4%. Net profit for the quarter stood at ₹3,368.8 crore, up 16.0% year-on-year from ₹2,903.4 crore reported in the corresponding quarter of the previous financial year.
Sun Pharma’s Global Innovative Medicines business delivered a notable performance during the quarter, reporting sales of US$ 423 million. This figure included a one-time milestone payment of US$ 55 million. Excluding the milestone income, Innovative Medicines sales grew 13.2% year-on-year and accounted for 21.2% of the company’s consolidated sales, underlining the increasing importance of specialty and innovative products in the overall business mix.
Investment in future growth remained steady, with research and development expenditure for Q3FY26 amounting to ₹892.8 crore. This represented 5.8% of quarterly sales, reflecting the company’s continued focus on strengthening its product pipeline and long-term competitiveness.
